Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Valganciclovir Hydrochloride

FDA-approved product (tablet, oral), marketed as Valcyte, Valganciclovir Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Valganciclovir Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • AIDS
  • Cytomegalovirus Retinitis
  • Retinitis
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AB14

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Valganciclovir Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Valganciclovir Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.

    NCT00275665 · start 2001-11

    Registered record
    Registry ID
    NCT00275665
    Conditions
    Bone Marrow Stem Cell Transplant
    Interventions
    Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-11
    Completion
    2007-07
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Marrow Stem Cell Transplant
    InterventionValganciclovir
    PhasePhase 3
    Registry statusCompleted

  • Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation

    NCT00016068 · start 2001-01

    Registered record
    Registry ID
    NCT00016068
    Conditions
    Infection
    Interventions
    ganciclovir; valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-01
    Completion
    2007-09
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    Interventionganciclovir; valganciclovir
    PhasePhase 3
    Registry statusCompleted

  • A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS

    NCT00002222

    Registered record
    Registry ID
    NCT00002222
    Conditions
    Cytomegalovirus Retinitis; HIV Infections
    Interventions
    Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Retinitis; HIV Infections
    InterventionValganciclovir
    PhaseNot applicable
    Registry statusCompleted

  • Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection

    NCT00017784

    Registered record
    Registry ID
    NCT00017784
    Conditions
    Cytomegalovirus Retinitis; HIV Infections
    Interventions
    Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Retinitis; HIV Infections
    InterventionValganciclovir
    PhasePhase 3
    Registry statusUnknown

  • B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

    NCT01049633

    Registered record
    Registry ID
    NCT01049633
    Conditions
    Type 1 Diabetes Mellitus
    Interventions
    Allogeneic Pancreatic Islet Cells; Sirolimus; Basiliximab; Tacrolimus; Antibacterial, Antifungal, and Antiviral Prophylaxis; Trimethoprim/sulfamethoxazole; Clotrimazole; Valganciclovir; Heparin; Enoxaparin; Pentoxifylline; Aspirin
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes Mellitus
    InterventionAllogeneic Pancreatic Islet Cells; Sirolimus; Basiliximab; Tacrolimus +8 more
    PhaseNot recorded
    Registry statusNo longer available